Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy hopes to tackle tough lymphoma

NCT ID NCT03533283

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This trial tests two new drug combinations (glofitamab plus atezolizumab or polatuzumab vedotin) in adults with B-cell non-Hodgkin lymphoma that has returned or not responded to prior treatment. The study aims to find the safest dose and see if these combos shrink tumors. About 211 participants will receive the drugs intravenously over several cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Glofitamab, atezolizumab, polatuzumab vedotin, obinutuzumab
What this could lead to
If successful, this could offer a new treatment option for people with hard-to-treat B-cell non-Hodgkin lymphoma, potentially improving response rates.
What could go wrong
This is an early-phase trial (phase 1/2) with a small number of participants, so results may not apply broadly. Side effects from the drug combinations could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKINS LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma follicular lymphoma high grade B-cell lymphoma high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangement marginal zone lymphoma non-Hodgkin lymphoma primary mediastinal large B-cell lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKINS LYMPHOMA

Contacts and locations

Locations

  • Aarhus Universitetshospital Skejby

    Aarhus N, 8200, Denmark

  • Asst Papa Giovanni Xxiii

    Bergamo, Lombardy, 24127, Italy

  • Chaim Sheba Medical Center

    Ramat Gan, 52621, Israel

  • Fond. IRCCS Istituto Nazionale Tumori

    Milan, Lombardy, 20133, Italy

  • Hadassah Ein Karem Hospital

    Jerusalem, 9112001, Israel

  • Hospital Clinico Universitario Virgen de la Victoria

    Málaga, 29010, Spain

  • Hospital Clinico Universitario de Valencia

    Valencia, 46010, Spain

  • Hospital Duran i Reynals

    Barcelona, 08907, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, 08035, Spain

  • Istituto Nazionale Tumori Irccs Fondazione g. Pascale

    Naples, Campania, 80131, Italy

  • Odense Universitetshospital

    Odense C, 5000, Denmark

  • Policlinico S.Orsola-Malpighi

    Bologna, Emilia-Romagna, 40138, Italy

  • Rabin Medical Center-Beilinson Campus

    Petah Tikva, 4941492, Israel

  • Rigshospitalet

    København Ø, 2100, Denmark

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • The HOPE Clinical Trials Unit

    Leicester, LE1 5WW, United Kingdom

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • UZ Gent

    Ghent, 9000, Belgium

  • University College London Hospitals NHS Foundation Trust

    London, W1T 7HA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.